Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 371

Microbes that are used for health, agricultural, or other applications need to be able to withstand extreme conditions, and ideally the manufacturing processes used to make tablets for long-term storage. MIT researchers have now developed a new way to make microbes hardy enough to withstand these extreme conditions.

Their method involves mixing bacteria with food and drug additives from a list of compounds that the FDA classifies as “generally regarded as safe.” The researchers identified formulations that help to stabilize several different types of microbes, including yeast and bacteria, and they showed that these formulations could withstand high temperatures, radiation, and industrial processing that can damage unprotected microbes.

In an even more extreme test, some of the microbes recently returned from a trip to the International Space Station, coordinated by Space Center Houston Manager of Science and Research Phyllis Friello, and the researchers are now analyzing how well the microbes were able to withstand those conditions.

Read more | >

This is a recording of the AGI23 Conference, Day 1, June 16th 2023, Stockholm. This video shows the following tutorial: Test and Evaluation First Principles for General Learning Systems, led by Tyler Cody.

SingularityNET was founded by Dr. Ben Goertzel with the mission of creating a decentralized, democratic, inclusive, and beneficial Artificial General Intelligence (AGI). An AGI is not dependent on any central entity, is open to anyone, and is not restricted to the narrow goals of a single corporation or even a single country.

The SingularityNET team includes seasoned engineers, scientists, researchers, entrepreneurs, and marketers. Our core platform and AI teams are further complemented by specialized teams devoted to application areas such as finance, robotics, biomedical AI, media, arts, and entertainment.

Website: https://singularitynet.io.
X: https://x.com/SingularityNET
Instagram: / singularitynet.io.
Discord: / discord.
Forum: https://community.singularitynet.io.
Telegram: https://t.me/singularitynet.
WhatsApp: https://whatsapp.com/channel/0029VaM8…
Warpcast: https://warpcast.com/singularitynet.
Mindplex Social: https://social.mindplex.ai/@Singulari…
Github: https://github.com/singnet.
Linkedin: / singularitynet.

Read more | >

Researchers from Sinai Health and the University of Toronto have gleaned new insights into how thyroid cancer could be more effectively treated.

The study, which looked at thyroid tumor tissues and thyroid nodule biopsies from 620 patients at Mount Sinai Hospital from 2016 to 2022, examined whether differences in patients’ RAS genomic variants were reflected in the status of their tumors. It also investigated the presence of the variant BRAF V600E and TERT promoter variants in the patient’s samples.

Researchers ultimately concluded that differences in RAS in combination with BRAF V600E and TERT promoter variants could be used to arrive at more accurate cancer diagnoses in patients with indeterminate thyroid nodules.

Read more | >

Treating cancer can sometimes feel like a game of Whac-A-Mole. The disease can become resistant to treatment, and clinicians never know when, where and what resistance might emerge, leaving them one step behind. But a team led by Penn State researchers has found a way to reprogram disease evolution and design tumors that are easier to treat.

They created a modular genetic circuit that turns cancer cells into a “Trojan horse,” causing them to self-destruct and kill nearby drug-resistant cancer cells. Tested in human cell lines and in mice as proof of concept, the circuit outsmarted a wide range of .

The findings were published today, July 4, in the journal Nature Biotechnology. The researchers also filed a provisional application to patent the technology described in the paper.

Read more | >

In this thought-provoking lecture, Prof. Jay Friedenberg from Manhattan College delves into the intricate interplay between cognitive science, artificial intelligence, and ethics. With nearly 30 years of teaching experience, Prof. Friedenberg discusses how visual perception research informs AI design, the implications of brain-machine interfaces, the role of creativity in both humans and AI, and the necessity for ethical considerations as technology evolves. He emphasizes the importance of human agency in shaping our technological future and explores the concept of universal values that could guide the development of AGI for the betterment of society.

00:00 Introduction to Jay Friedenberg.
01:02 Connecting Cognitive Science and AI
02:36 Human Augmentation and Technology.
03:50 Brain-Machine Interfaces.
05:43 Balancing Optimism and Caution in AI
07:52 Free Will vs Determinism.
12:34 Creativity in Humans and Machines.
16:45 Ethics and Value Alignment in AI
20:09 Conclusion and Future Work.

SingularityNET was founded by Dr. Ben Goertzel with the mission of creating a decentralized, democratic, inclusive, and beneficial Artificial General Intelligence (AGI). An AGI is not dependent on any central entity, is open to anyone, and is not restricted to the narrow goals of a single corporation or even a single country.

The SingularityNET team includes seasoned engineers, scientists, researchers, entrepreneurs, and marketers. Our core platform and AI teams are further complemented by specialized teams devoted to application areas such as finance, robotics, biomedical AI, media, arts, and entertainment.

Website: https://singularitynet.io.
X: https://x.com/SingularityNET
Instagram: / singularitynet.io.
Discord: / discord.
Forum: https://community.singularitynet.io.
Telegram: https://t.me/singularitynet.
WhatsApp: https://whatsapp.com/channel/0029VaM8…
Warpcast: https://warpcast.com/singularitynet.
Mindplex Social: https://social.mindplex.ai/@Singulari…
Github: https://github.com/singnet.
Linkedin: / singularitynet.

Read more | >

In this study we show that residual muscle–tendon afferents enable a person with transtibial amputation to directly neuromodulate biomimetic locomotion, enabling neuroprosthetic adaptations to varying walking speeds, terrains and perturbations. Such versatile and biomimetic gait has not been attainable in contemporary bionic legs without the reliance upon predefined intrinsic control frameworks1,2. Central to the improved neural controllability demonstrated in this study are muscle–tendon sensory organs26,27 that deliver proprioceptive afferents. The surgically reconstructed, agonist–antagonist muscles emulate natural agonistic contraction and antagonistic stretch, thereby generating proprioceptive afferents corresponding to residual muscle movements.

During the ground contact phase of walking, the reconstructed muscle–tendon dynamics of the AMI do not precisely emulate intact biological muscle dynamics. The residual muscles of the AMI contract and stretch freely within the amputated residuum, only pulling against one another and not against the external environment. In distinction, for intact biological limbs, the muscle–tendons span the ankle joint, exerting large forces through an interaction with the external environment. These interactive muscle–tendon dynamics in intact biological limbs are believed to play a critical role in spinal reflexes, in addition to providing feedback for volitional motor control12. Therefore, for this study, the demonstrated capacity of augmented afferents to enable biomimetic gait neuromodulation is surprising given that their total magnitude is largely reduced compared with those of intact biological limbs26,27,45,46.

Read more | >

Neurological disorders, such as trauma, stroke, epilepsy, and various neurodegenerative diseases, often lead to the permanent loss of neurons, causing significant impairments in brain function. Current treatment options are limited, primarily due to the challenge of replacing lost neurons.

Direct neuronal , a complex procedure that involves changing the function of one type of cell into another, offers a promising strategy.

In cell culture and in living organisms, glial cells—the non-neuronal cells in the central nervous system—have been successfully transformed into functional neurons. However, the processes involved in this reprogramming are complex and require further understanding. This complexity presents a challenge, but also a motivation, for researchers in the field of neuroscience and regenerative medicine.

Read more | >

Arc Institute scientists have discovered the bridge recombinase mechanism, a revolutionary tool that enables fully programmable DNA rearrangements.

Their finding, detailed in a recent Nature publication, is the first DNA recombinase that uses a non-coding RNA for sequence-specific selection of target and donor DNA molecules. This bridge RNA is programmable, allowing the user to specify any desired genomic target sequence and any donor DNA molecule to be inserted.

The research was developed in collaboration with the labs of Silvana Konermann, Arc Institute Core Investigator and Stanford University Assistant Professor of Biochemistry, and Hiroshi Nishimasu, Professor of Structural Biology at the University of Tokyo.

Read more | >